• Prescribing Information
• Indication and Important Safety Considerations
• Site Map
• Register for Updates

• Home
• About ZOMIG
• HCP Resources
• Resources for Your Patients
  • Patient Downloads
  • Today’s Migraineur
• ZOMIG Virtual Rep

Here are resources you can share with today’s migraineurs to help them track their migraines, learn more about migraines, and talk to you about migraine management while they keep pace with their busy lives.

Migraine Tracker

This migraine tracker will encourage your patients to track and discuss the pattern of their migraines.

This easy-to-use migraine diary will help your patients record their migraine triggers, pain intensity, pain duration, and effectiveness of treatment each time they experience a migraine. This information may prove helpful as you and your patients work out a migraine management plan that works best for them.

Download as PDF

MIDAS Disability Assessment Scale

MIDAS helps your patients tell you about the impact of their migraines.

Migraine Disability Assessment Scale (MIDAS) is a treatment management tool designed to further assist you and your patients to determine the impact of migraine on patients’ lives to form the most effective course of treatment.

Select the MIDAS that best fits your practice:

Migraine Trigger Chart

Even though the actual cause of migraines has not been determined, certain foods and physical/emotional situations may help set off, or trigger, migraines. Using the chart below to help your patients know what their individual triggers are could help you determine a migraine management plan that works for them.

Download as PDF

Patient Web Site for ZOMIG

Encourage your patients to visit our patient-focused www.ZOMIG.com.

Here patients can find special programs and materials about migraine pain, its treatment, and what they can do to help ensure the success of their migraine treatment program.

Patient Web Resources

News, migraine information, and migraine support 24/7

Provide your patients with a listing of online resources that they can access day or night for educational information, migraine support groups, and message boards, available at our patient-focused www.zomig.com/what/resources.aspx.

Download as PDF

Indication and Important Safety Considerations

ZOMIG is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established.
ZOMIG is not intended for the prophylactic therapy of migraine and is not indicated for the treatment of cluster headache.
• ZOMIG is contraindicated in patients with
• -  Ischemic heart disease (eg, silent ischemia, angina), coronary artery vasospasm, or other significant underlying cardiovascular disease
• -  Cerebrovascular syndromes (eg, history of stroke or TIA)
• -  Peripheral vascular disease (eg, ischemic bowel disease)
• -  Uncontrolled hypertension
• Use of ZOMIG is contraindicated within 24 hours of another 5-HT₁ agonist, ergotamine-containing or ergot-type medication, or within 2 weeks of an MAO-A inhibitor
• ZOMIG should not be administered to patients with hemiplegic or basilar migraine
• It is strongly recommended that ZOMIG not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors without a satisfactory cardiac evaluation
• Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other accessory cardiac conduction pathways should not receive ZOMIG
• Development of potentially life-threatening serotonin syndrome may occur with triptans particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
• Phenylketonuric patients should be informed that ZOMIG-ZMT^® (zolmitriptan) contains phenylalanine
• ZOMIG should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus
• Most common adverse reactions in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
• Most common adverse reactions in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness